{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-095512","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2026-08-13T12:50:09+00:00","discovered_at":"2026-08-13T12:55:00.239418+00:00","generated_at":"2026-08-13T12:55:06.901692+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Dogwood Q2 net loss $11.5M; Halneuron Phase 2b on track, 217 patients enrolled","bullets":["Net loss $11.5M ($0.34/share) vs $3.8M ($1.99/share) in Q2 2025; includes $6.7M non-cash IPR&D impairment.","Cash $9.6M provides runway through Q4 2026 Phase 2b readout; R&D $3.2M, G&A $1.6M.","Halneuron Phase 2b CINP trial: 217 patients enrolled, top-line results expected fall 2026; 12-week extension study started.","SP16 granted FDA IND approval; NCI-funded study at UVA to start H2 2026.","Appointed Iain Dukes (OrbiMed) as Scientific Advisory Board Chair; legacy antiviral partnership worth up to $100M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-095512","json":"https://secwatch.observer/filing/0001104659-26-095512.json","markdown":"https://secwatch.observer/filing/0001104659-26-095512.md","text":"https://secwatch.observer/filing/0001104659-26-095512.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000110465926095512/0001104659-26-095512-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000110465926095512/dwtx-20260813x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T12:55:06.901692+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}